Method for the Quantitative Characterisation of Amyloid And/or Aggregating Peptides And/or Proteins in a Sample

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method for the quantitative analysis of amyloid and/or aggregating peptides and proteins in a sample. The process involves preparing a sample, introducing a test compound (potential drug), separating protein aggregates by their size and shape (e.g., using density gradient centrifugation), optionally denaturing these aggregates to monomers, and measuring the concentration changes in each fraction. By comparing the concentrations with and without the test compound, one can quantitatively assess the effect of drug candidates on various amyloid or protein aggregates, which are significant in diseases like Alzheimer's.

Use CasesContent extracted from patent full text and abstract with AI.

• Screening potential therapeutic compounds targeting amyloid-beta oligomers related to Alzheimer's disease.
• Quantitative analysis of protein aggregation in neurodegenerative disease research.
• Evaluating drug efficacy on reducing toxic protein aggregates in vitro before costly animal or clinical trials.
• Characterizing aggregate size and form distributions in protein misfolding disorders such as Parkinson's or prion diseases.
• Quality control in biotechnology processes where protein aggregation is critical.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides precise, quantitative measurement of protein aggregate species and their changes upon drug treatment.
• Allows high-throughput and reproducible screening of multiple compounds, accelerating drug discovery.
• Overcomes limitations of antibody-based or semi-quantitative methods by directly analyzing aggregate size and form.
• Enables identification and selection of the most effective compounds in reducing toxic protein species.
• Independent of epitope availability, enabling broader applicability to various aggregate types and sample sources.
• Reduces time and cost by improving the predictive power of in vitro assays before advancing to animal/human testing.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a method for the quantitative characterisation of amyloid and/or aggregated peptides and/or proteins in a sample, comprising the following steps: preparing a sample containing an amyloid and/or aggregated peptide and/or protein having at least one aggregate size and shape; adding an active ingredient to be analysed to the sample solution; separating the amyloid and/or aggregated peptides and/or proteins from one another according to their aggregate size and shape; optionally completely denaturing the amyloid and/or aggregated peptides and/or proteins of a particular fraction into monomer units; comparing against control values without the active ingredient in order to determine the change in concentration of the peptide and/or protein units in at least one fraction.